Pharmacy Updates

“The humanitarian situation in Gaza is simply unbearable. Two million people don’t know where to go, what to eat, or how to get medical care. The health system is collapsing. Aid must be allowed in—now.” — @TDellaLonga, @IFRC Spokesperson, speaking to @TRTWorldNow We call for urgent, sustained access for humanitarian aid, protection for civilians, and safety for our colleagues risking everything to help.

Israel has bombed al-Ahli Hospital, putting north Gaza’s last functioning medical facility out of service. Critically ill Palestinian patients were forced to flee the Christian hospital before dawn on Palm Sunday with only a moment’s notice.

Ads for products that promise to supercharge the body’s immune system make claims that sound too good to be true. But do these products actually work?#HarvardHealth bit.ly/3ZFiolr

As the field of #CellAndGene therapies expands, medical and healthcare communication experts play a critical role in their evolution and impact. Chief Medical Officer, Dan Zaksas shared his insights in a new article: bit.ly/3qxlzOe #FH #FishawackHealth #FishwackOncology

We announced today global regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. Read more: investors.modernatx.com/news/news-deta….

An inhaled Covid vaccine booster was more than 5-fold effective for inducing neutralizing antibodies at 28-days, and more durable at 1-year, than shots, vs Omicron BA.5 in a randomized trial thelancet.com/journals/lanin… @TheLancetInfDis

#livertwitter Had a great time learning about the amazing research being conducted by such a cohesive group of researchers @IUGastro kudos to @nagachalasani @alhaddad_mo @rajVuppaLanchi for creating a beacon of clinical investigation in mid-west @IUGastro ! Gratitude 🙏 @UCSD_GI

People who are overweight are flocking to Ozempic to slim down, but looming is Lilly's even more powerful weight-loss treatment, called Mounjaro. trib.al/KxTFgUO

One community. One question, countless stories. This Myeloma Action Month: The Global Multiple Myeloma Community Comes Together to Raise Awareness. youtu.be/4HAM7NzPEEs #MYelomaStory

#MultipleMyeloma affects 160,000 patients each day, plus their families and caregivers. #MultipleMyelomaAwarenessMonth #FishawackHealth #FH

Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale fiercebiotech.com/biotech/pfizer…

I reviewed all we know about the XBB.1.5 variant 10 days ago, w/its high transmissibility erictopol.substack.com/p/a-new-varian… The ? now is whether it will have a material impact on adverse outcomes, for which there is some evidence among seniors in states with >75%

Takeda is buying Nimbus’ late-stage TYK2 inhibitor for $4 billion in cash upfront — its largest single-asset purchase ever. endpts.com/in-its-largest…

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown fiercebiotech.com/biotech/roche-…

For the first time, a treatment alters the course of Type 1 diabetes, a disease that typically emerges in adolescence. The 14-day therapy’s estimated cost is nearly $200,000. nyti.ms/3i0Jn8Y

The consistent increased risk of diabetes after Covid across all age groups, highest in the first 3 months after infection, from a systematic review of 9 studies, ~40 million people bmcmedicine.biomedcentral.com/articles/10.11…

Astellas' antibody zolbetuximab aces its PhIII trial in gastric cancer, meeting both its primary and secondary endpoints. endpts.com/astellas-spotl…

Novo Nordisk and GSK join Eli Lilly in pausing, or halting entirely, their ad spends on Twitter following Musk's tumultuous takeover. endpts.com/novo-nordisk-g…

Regeneron signed a licensing deal with CytomX on Thursday morning, ponying up $30 million upfront to work together on bispecific cancer treatments. endpts.com/regeneron-thro…

Roche adds Navify digital solutions to its digital health portfolio at HLTH 2022 labpulse.com/diagnostic-tec…